Effect of glucocorticoid-, parathyroid- and thyroid hormones excess on human iliac crest bone matrix insulin-like growth factor (IGF)-I in patients with osteoporosis.
Insulin-like growth factor-I (IGF-I) is a well documented bone-active growth factor. Clinical studies reported that circulating hormones may affect serum IGF-I levels, with potential consequences on bone remodeling. However, no data on bone matrix concentrations of IGF-I in subjects with endocrine dysfunction is available in humans. Bone mineral density and cancellous bone matrix IGF-I levels were assessed in iliac crest biopsies from 38 patients with low bone mass related to glucocorticoid- (n=10), parathyroid- (n=14) or thyroid (n=14) hormones excess. Results were compared to those of sex- and age-matched patients with primary osteoporosis. Bone matrix extraction was performed based on a guanidine-chlorhidric acid/ethylendiamine-tetraacetic acid method. Long-term glucocorticoid therapy (> or =24 months) led to significantly lower cancellous bone matrix IGF-I levels in comparison to age-matched controls (p=0.03). Although higher trabecular bone IGF-I levels were seen in hyperparathyroid subjects, the difference was not significant in comparison to controls (p=0.24). Likewise, no difference was noticed in cancellous bone matrix IGF-I concentrations between subjects with low bone mass and sub-clinical or overt thyrotoxicosis and euthyroid controls. Neither parathyroid hormone (PTH) nor thyroxin (T (4)) concentrations were associated with bone matrix IGF-I levels. To conclude, our study documented that in vivo long-term corticotherapy is associated with low trabecular human bone matrix IGF-I. In contrast, no influence of increased circulating parathyroid- or thyroid hormones levels on human iliac crest skeletal IGF-I concentrations was observed.
Pepene
C E
CE
University of Medicine and Pharmacy Cluj-Napoca, Endocrinology, Cluj-Napoca, Romania.
Seck
T
T
Diel
I
I
Minne
H W
HW
Ziegler
R
R
Pfeilschifter
J
J
D015519:Bone Density; D001857:Bone Matrix / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications / Q000188:drug therapy; D007085:Ilium / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D007334:Insulin-Like Growth Factor I / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D010281:Parathyroid Hormone / Q000494:pharmacology*; D011241:Prednisone / Q000494:pharmacology / Q000627:therapeutic use; D013963:Thyroid Hormones / Q000494:pharmacology*; D013971:Thyrotoxicosis / Q000150:complications / Q000188:drug therapy
D005938:Glucocorticoids; D010281:Parathyroid Hormone; D013963:Thyroid Hormones; D007334:Insulin-Like Growth Factor I; D011241:Prednisone